Search Results

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies (TTX-080-001) MOA: TX-080 is an anti-HLA-G antibody that binds specifically to HLA-G and blocks engagement with ILT2 and ILT4 and reverses HLA-G-mediated immunosuppression. Key Eligibility Criteria: Histologically or…

Have you been recently diagnosed? Facing a new cancer diagnosis can be overwhelming, but you don’t have to face any of it alone. Here are quick links to new patient resources to help with next steps: Read and review common questions and answers regarding diagnosis Schedule a new patient appointment Learn what to expect during…

Dr. Andrew Li is a medical oncologist and hematologist at Maryland Oncology Hematology. Dr. Li received his medical degree from Virginia Tech Carilion School Medicine before completing a residency in internal medicine at the University of Maryland Medical Center. He went on to complete an oncology and hematology fellowship at the University of Maryland Marlene…

Dr. Dong (Jake) Kim is an oncologist and hematologist at Maryland Oncology Hematology’s Silver Spring and Hyattsville locations. Dr. Kim received his medical degree from the University of Maryland School of Medicine, where he also completed a residency in internal medicine. He then went on to complete a fellowship in oncology and hematology at Fox…

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors MOA: ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase CHK1.…